Research indicates that autologous dendritic cell‐tumor vaccine therapy has shown promising outcomes, including initial tumor shrinkage, elevated levels of tumor‐infiltrating CD8(+) lymphocytes, and improved median survival rates (525 days) and 5‐year survival rates (18.8%) in patients with grade IV glioma compared to historical control cohorts (median survival of 380 days and 5‐year survival of 0%).109. This evidence concerns the gene CD8A and glioma.